文献速递类风湿关节炎

巴瑞替尼单药与联合治疗RA的长期疗效、耐受性及药物留存率比较:真实世界前瞻性队列研究

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study.
PubMed 文献 · RMD Open · 2025-12-17

该单中心前瞻性观察队列纳入219例起始巴瑞替尼的RA患者(单药165例、联合54例),基线平均DAS28-ESR 4.0;两组均快速持续改善,6个月时疾病活动度稳定于低水平,33%达Boolean缓解且组间无显著差异(p=0.35),中位药物留存36个月且组间相似(log-rank p=0.82),因不良事件停药10.9%。

要点

  • 巴瑞替尼单药与联合MTX在长期疗效和药物留存上表现相似。
  • 33%患者达Boolean缓解,两组无显著差异(p=0.35)。
  • 因不良事件停药10.9%,4例血栓事件均见于已有心血管危险因素者。

核心结论

  • 在真实世界RA队列中,巴瑞替尼单药与联合MTX的长期疗效、药物留存率相似,安全性可接受。
  • 对MTX不适合或不耐受的RA患者,巴瑞替尼单药可有效使用。

研究设计与样本

  • 单中心前瞻性观察队列,分析2017至2023年间219例起始巴瑞替尼的RA患者。
  • 每3个月收集临床数据、患者报告结局与安全性事件,采用Kaplan-Meier法分析药物留存、线性混合效应模型评估纵向结局。

主要发现

  • 队列共219例(单药165例、联合54例),基线平均DAS28-ESR为4.0。
  • 两组均快速且持续临床改善,治疗6个月时疾病活动度稳定于低水平。
  • 72例(33%)达Boolean缓解,组间无显著差异(p=0.35)。
  • 中位药物留存36个月,两种方案相似(log-rank p=0.82)。
  • 因不良事件停药占10.9%,记录4例血栓事件,均见于已有心血管危险因素患者,未见新安全性信号。

关键数值与推荐

  • Boolean缓解率33%(n=72),单药与联合组间p=0.35。
  • 中位药物留存36个月,组间log-rank p=0.82。
  • 因不良事件停药率10.9%。

临床怎么用

  • 对MTX不适合或不耐受的RA患者,可考虑巴瑞替尼单药治疗。
  • 已有心血管危险因素者使用巴瑞替尼需关注血栓事件风险。

局限性

  • 单中心前瞻性观察队列,单药组165例与联合组54例样本量不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Janus kinase inhibitors (JAKi), like baricitinib, are used as monotherapy (MONO) and in combination with methotrexate (MTX) in rheumatoid arthritis (RA) patients. This study aimed to evaluate the long-term efficacy, drug survival and safety of baricitinib MONO versus combination therapy (COMBO) in a prospective cohort of patients with RA. METHODS: We analysed data from 219 RA patients initiating baricitinib in a single-centre, prospective observational cohort between 2017 and 2023. Clinical data, patient-reported outcomes and safety events were collected every 3 months. Drug survival was analysed using the Kaplan-Meier method, and longitudinal outcomes were assessed using linear mixed-effects models. RESULTS: The cohort included 219 patients (165 MONO, 54 COMBO) with high baseline disease activity (mean DAS28-ESR 4.0). Both groups showed rapid and sustained clinical improvement, with disease activity stabilising in the low range by 6 months of treatment. One third of the patients (n=72, 33%) achieved Boolean remission, with no significant difference between groups (p=0.35). Median drug survival was 36 months and was similar for both regimens (log-rank p=0.82). Discontinuation due to adverse events occurred in 10.9% of patients. Four thrombotic events were noted, all in patients with pre-existing cardiovascular risk factors, with no new safety signals emerging. CONCLUSIONS: In this real-world cohort, baricitinib demonstrated sustained long-term effectiveness, drug survival and an acceptable safety profile. The similar outcomes observed for MONO and COMBO indicate that baricitinib may be used effectively as MONO in patients with RA for whom MTX is not suitable or tolerated.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Temiz A, Tascilar K, Kleyer A, et al. Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study. RMD Open. 2025. PMID: 41407433. doi:10.1136/rmdopen-2025-006333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。